A decade ago, we showed that the UK government wasted over £500 million on stockpiling antivirals for the next “influenza” pandemic. It apparently justified its decision on the basis of the usual models and pharma-sponsored ghost-written trials.
After four years of analysing the data for clinical study reports on antivirals, our Cochrane review reported …